When and How to Switch to Tirzepatide or Dual-Peptide Therapy Tirzepatide's dual GIP and GLP-1 receptor activation typically produces 2022% body weight reduction in clinical studies, compared to semaglutide's 1518%
Many DSIP failures trace back to incorrect mixing that either destroys the peptide or makes precise dosing impossible
Semaglutide is available by prescription only
So I think seeing the progression of that and looking at outcome studies will be key before we make a decision of whether or not we want to include that in our care. Road to Reimbursement Because GLP-1s are a new drug within health care in general and there are not yet any clinical standards for its use across substance use disorder care, serious mental illnesses or eating disorders, the road to eventual reimbursement for including it in care is one all practitioners told BHB they will be closely monitoring
Individual Response Varies: The Role of Genetic Predisposition The PlexusDx Precision Peptide Genetic Test analyzes GLP1R, FTO, and MC4R variants that relate to GLP-1 and related signaling pathways
The concept is straightforward: after reaching goal weight, reduce to a lower dose (perhaps 4mg or 8mg) that maintains appetite suppression and metabolic benefits without the full side effect profile or cost of the maximum dose
